Results 111 to 120 of about 73,193 (159)

Malignancy and Janus Kinase Inhibition

Rheumatic Disease Clinics of North America, 2017
The use of biologics such as anti-tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung cancer, and nonmelanoma skin cancers (NMSCs) is greater in patients with RA compared with the general population.
Padmapriya, Sivaraman, Stanley B, Cohen
openaire   +2 more sources

Janus kinases in cytokine signalling

Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 1996
Abstract Hematopoiesis is largely regulated by the binding of cytokines to receptors of the cytokine receptor superfamily. Although lacking catalytic domains, members of the cytokine receptor superfamily mediate ligand dependent activation of tyrosine phosphorylation which is critical for all receptor functions.
James N. Ihle, Christopher John Marshall
openaire   +2 more sources

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Mapping the kinase domain of janus kinase 3

Bioorganic & Medicinal Chemistry Letters, 2003
The utilization and impact of parallel synthesis on lead exploration around initial hit oxindole (1) are described. The emergent SAR, analogue design and functional impact will also be detailed.
Christopher, Adams, David J, Aldous, Shelley, Amendola, Paul, Bamborough, Colin, Bright, Sarah, Crowe, Paul, Eastwood, Garry, Fenton, Martyn, Foster, Trevor K P, Harrison, Sue, King, Justine, Lai, Christopher, Lawrence, Jean-Philippe, Letallec, Clive, McCarthy, Neil, Moorcroft, Kenneth, Page, Sudha, Rao, Jane, Redford, Shazia, Sadiq, Keith, Smith, John E, Souness, Sukanthini, Thurairatnam, Mark, Vine, Barry, Wyman   +24 more
openaire   +2 more sources

Janus-Kinase-Hemmer

Zeitschrift für Rheumatologie, 2012
Die Janus-Kinase-Inhibitoren stellen einen neuen therapeutischen Ansatz in der Behandlung der rheumatoiden Arthritis dar. In Phase-II- und -III-Studien zu Tofacitinib zeigte sich eine gute klinische Wirksamkeit mit einem ACR (American College of Rheumatology)-20-Ansprechen von > 50% sowohl fur die Mono- als auch die Kombinationstherapie mit Methotrexat.
E. Ostermeier, P. Roll, H.-P. Tony
openaire   +1 more source

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J., Cardona A.F., Anand V., Solà I.   +3 more
openaire   +2 more sources

Janus Kinase Inhibitors

2017
To control gene expression, cytokines and other extracellular molecules utilize the Janus kinase (JAK) and signal transducers and activators of transcription (STAT). Dysregulation of the JAK-STAT pathway has been implicated in a myriad of inflammatory and hematologic disorders.
Andrew Kim, Bruce Strober
openaire   +1 more source

Janus Kinase

2021
Bobin George Abraham, Juuli Raivola, Anniina Virtanen, Olli Silvennoinen   +3 more
openaire   +1 more source

[Janus kinase inhibitors].

Zeitschrift fur Rheumatologie, 2022
In 2017 the first Janus kinase (JAK) inhibitors were approved for the treatment of rheumatoid arthritis in Germany. The mode of action of JAK inhibitors differs from biologicals, as multiple cytokines are inhibited. In comparison with the treatment with biologicals, JAK inhibitors have the advantage of oral application, three of the four currently ...
openaire   +1 more source

[Janus kinase inhibitors].

Zeitschrift fur Rheumatologie, 2013
Janus protein tyrosine kinase (JAK) inhibitors are new therapeutic targets in the treatment of rheumatoid arthritis. Tofacitinib has shown good clinical efficacy in phase II and III studies with American College of Rheumatology (ACR) 20 response rates over 50% for monotherapy and in combination with methotrexate (MTX).
E, Ostermeier, P, Roll, H-P, Tony
openaire   +1 more source